BridgeBio Pharma appoints Thomas Trimarchi as President and CFO; former CFO departs

BridgeBio Pharma, Inc.

Brian Stephenson's employment ended March 17, 2025; receives 9 months base salary and COBRA.
Stephenson to serve as consultant from March 17, 2025 through March 17, 2026.
Thomas Trimarchi appointed President and CFO; effective immediately.
Stephenson's departure is for personal reasons and not due to any disagreement with the company.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian C. Stephenson

Chief Financial Officer

BBIO · BridgeBio Pharma, Inc.

Effective: 2025-03-17
Successor: Thomas Trimarchi
Filed: March 17, 2025, 7:59 PM ET

The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian C. Stephenson departed as Chief Financial Officer at BridgeBio Pharma, Inc..

Action: ended
Role: Chief Financial Officer

Exact text from the filing

The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective Date”).

View on SEC.gov

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-25-009063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.